Skip to Content

Replimune Group, Inc.

Securities Class Action

  • Date:
  • 10/5/2026
  • Company Name:
  • Replimune Group Inc.
  • Stock Symbol:
  • REPL
  • Class Period:
  • FROM 10/25/2025 TO 4/10/2026
  • Status:
  • Filed
  • Filing Date:
  • 8/6/2026

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ:REPL) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Replimune securities between  October 20, 2025 and April 10, 2026, both dates inclusive (the “Class Period”). Investors have until October 5, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) in connection with the Biologics License Application (“BLA”), the study design concerns previously communicated by the FDA were not addressed; (2) Replimune had submitted data from an early unplanned analysis from RP1-104, which included only 40 patients (10% of the planned enrollment of 400 patients); and (3) as a result, RPL-001-16 and RP1-104 both had deficiencies which were likely to cause the FDA to reject the BLA.

If you purchased or otherwise acquired Replimune shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Replimune Group Inc. . BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: